References
- Ramanan VK, Saykin AJ. Pathways to neurodegeneration: mechanistic insights from GWAS in Alzheimer’s disease, Parkinson’s disease, and related disorders. Am J Neurodegener Dis. 2013;2(3):145–75.
- Lee DR, Taylor JP, Thomas AJ. Assessment of cognitive fluctuation in dementia: a systematic review of the literature. Int J Geriatr Psychiatry. 2012;27(10):989–98. doi:https://doi.org/10.1002/gps.2823.
- Chauhan NB, Mehla J. Chapter 27 - Ameliorative effects of nutraceuticals in neurological disorders. In: Ronald Ross Watson and Victor R. Preedy, editors. Bioactive nutraceuticals and dietary supplements in neurological and brain disease. Academic Press; 2015. p. 245–60. doi:https://doi.org/10.1016/B978-0-12-411462-3.00027-8.
- Singh HK. Brain enhancing ingredients from āyurvedic medicine: quintessential example of bacopa monniera, a narrative review. Nutrients. 2013;5(2):478–97. doi:https://doi.org/10.3390/nu5020478.
- Joseph J, Cole G, Head E, Ingram D. Nutrition, brain aging, and neurodegeneration. J Neurosci. 2009;29(41):12795–801. doi:https://doi.org/10.1523/JNEUROSCI.3520-09.2009.
- Nakamura T, Lipton SA. S-Nitrosylation and uncompetitive/fast off-rate (UFO) drug therapy in neurodegenerative disorders of protein misfolding. Cell Death Differ. 2007;14(7):1305–14. doi:https://doi.org/10.1038/sj.cdd.4402138.
- Prince M, Prina M, Guerchet M. World Alzheimer report 2013. Alzheimer’s Dis Int. 2013:1–92.
- Da Costa Dias B, Jovanovic K, Gonsalves D, Weiss SFT. Structural and mechanistic commonalities of amyloid-beta and the prion protein. Prion. 2011;5(3):126–37. doi:https://doi.org/10.4161/pri.5.3.17025.
- Peden AH, Ironside JW. Molecular pathology in neurodegenerative diseases. Curr Drug Targets. 2012;13(12):1548–59. doi:https://doi.org/10.2174/138945012803530134.
- Holmes BB, Diamond MI. Cellular mechanisms of protein aggregate propagation. Curr Opin Neurol. 2012;25(6):721–6. doi:https://doi.org/10.1097/WCO.0b013e32835a3ee0.
- Agnihotri A, Aruoma OI. Alzheimer’s disease and Parkinson’s disease: a nutritional toxicology perspective of the impact of oxidative stress, mitochondrial dysfunction, nutrigenomics and environmental chemicals. J Am Coll Nutr. 2020;39(1):16–27. doi:https://doi.org/10.1080/07315724.2019.1683379.
- Celotto AM, Palladino MJ. Drosophila: a “model” model system to study neurodegeneration. Mol Interv. 2005;5(5):292–303. doi:https://doi.org/10.1124/mi.5.5.9.
- Pandey UB, Nichols CD. Human disease models in Drosophila melanogaster and the role of the fly in therapeutic drug discovery. Pharmacol Rev. 2011;63(2):411–36. doi:https://doi.org/10.1124/pr.110.003293.
- Singh MP, Krishna Reddy MM, Mathur N, Saxena DK, Kar Chowdhuri D. Induction of hsp70, hsp60, hsp83 and hsp26 and oxidative stress markers in benzene, toluene and xylene exposed Drosophila melanogaster: role of ROS generation. Toxicol Appl Pharmacol. 2009;235(2):226–43. doi: https://doi.org/10.1016/j.taap.2008.12.002.
- Singh MP, Ram KR, Mishra M, Shrivastava M, Saxena DK, Chowdhuri DK. Effects of co-exposure of benzene, toluene and xylene to Drosophila melanogaster: alteration in hsp70, hsp60, hsp83, hsp26, ROS generation and oxidative stress markers. Chemosphere. 2010;79(5):577–87. doi:https://doi.org/10.1016/j.chemosphere.2010.01.054.
- Kumar A, Tiwari AK. Molecular chaperone Hsp70 and its constitutively active form Hsc70 play an indispensable role during eye development of Drosophila melanogaster. Mol Neurobiol. 2018;55(5):4345–61. doi:https://doi.org/10.1007/s12035-017-0650-z.
- Bonini NM. Chaperoning brain degeneration. Proc Natl Acad Sci USA. 2002;99(Supplement 4):16407–11. doi:https://doi.org/10.1073/pnas.152330499.
- Marsh JL, Thompson LM. Can flies help humans treat neurodegenerative diseases? Bioessays. 2004;26(5):485–96. doi:https://doi.org/10.1002/bies.20029.
- Bonini NM. Drosophila as a genetic approach to human neurodegenerative disease. Parkinsonism Relat Disord. 2001;7(3):171–5. doi:https://doi.org/10.1016/S1353-8020(00)00054-7.
- Reiter LT, Potocki L, Chien S, Gribskov M, Bier E. A systematic analysis of human disease-associated gene sequences in Drosophila melanogaster. Genom Res. 2001;11(6):1114–25. doi:https://doi.org/10.1101/gr.169101.
- Tucker D, Lu Y, Zhang Q. From mitochondrial function to neuroprotection—an emerging role for methylene blue. Mol Neurobiol. 2018;55(6):5137–53. doi:https://doi.org/10.1007/s12035-017-0712-2.
- Deng S, Liu H, Qiu K, You H, Lei Q, Lu W. Role of the Golgi apparatus in the blood-brain barrier: Golgi protection may be a targeted therapy for neurological diseases. Mol Neurobiol. 2018;55(6):4788–801. doi:https://doi.org/10.1007/s12035-017-0691-3.
- Mazzio EA, Close F, Soliman KFA. The biochemical and cellular basis for nutraceutical strategies to attenuate neurodegeneration in Parkinson’s disease. Int J Mol Sci. 2011;12(1):506–69. doi:https://doi.org/10.3390/ijms12010506.
- Qazi TJ, Quan Z, Mir A, Qing H. Epigenetics in Alzheimer’s disease: perspective of DNA methylation. Mol Neurobiol. 2018;55(2):1026–44. doi:https://doi.org/10.1007/s12035-016-0357-6.
- Rubin GM. Comparative genomics of the eukaryotes. Science. 2000;287(5461):2204–15. doi:https://doi.org/10.1126/science.287.5461.2204.
- Fortini ME, Bonini NM. Modeling human neurodegenerative diseases in Drosophila: on a wing and a prayer. Trends Genet. 2000;16(4):161–7. doi:https://doi.org/10.1016/S0168-9525(99)01939-3.
- Coombe PE, Heisenberg M. The structural brain mutant vacuolar medulla of Drosophila melanogaster with specific behavioral defects and cell degeneration in the adult. J Neurogenet. 1986;3(3):135–58. doi:https://doi.org/10.3109/01677068609106845.
- Buchanan RL, Benzer S. Defective glia in the Drosophila brain degeneration mutant drop-dead. Neuron. 1993;10(5):839–50. doi:https://doi.org/10.1016/0896-6273(93)90200-B.
- Palladino MJ, Bower JE, Kreber R, Ganetzky B. Neural dysfunction and neurodegeneration in Drosophila Na+/K + ATPase alpha subunit mutants. J Neurosci. 2003;23(4):1276–86. doi:https://doi.org/10.1523/JNEUROSCI.23-04-01276.2003.
- Rasool M, Malik A, Qureshi MS, Manan A, Pushparaj PN, Asif M, Qazi MH, Qazi AM, Kamal MA, Gan SH, et al. Recent updates in the treatment of neurodegenerative disorders using natural compounds. Evid-Based Complement Alternat Med. 2014;2014:1–7. doi:https://doi.org/10.1155/2014/979730.
- Alexander AG, Marfil V, Li C. Use of Caenorhabditis elegans as a model to study Alzheimer’s disease and other neurodegenerative diseases. Front Genet. 2014;5:279. doi:https://doi.org/10.3389/fgene.2014.00279.
- Venkatesan R, Ji E, Kim SY. Phytochemicals that regulate neurodegenerative disease by targeting neurotrophins: a comprehensive review. Biomed Res Int. 2015;2015:814068. doi:https://doi.org/10.1155/2015/814068.
- Lee S, Bang SM, Lee JW, Cho KS. Evaluation of traditional medicines for neurodegenerative diseases using Drosophila models. Evid-Based Complement Alternat Med. 2014;2014:1–14. doi:https://doi.org/10.1155/2014/967462.
- Driscoll M, Gerstbrein B. Dying for a cause: invertebrate genetics takes on human neurodegeneration. Nat Rev Genet. 2003;4(3):181–94. doi:https://doi.org/10.1038/nrg1018.
- Jeibmann A, Paulus W. Drosophila melanogaster as a model organism of brain diseases. Int J Mol Sci. 2009;10(2):407–40. doi:https://doi.org/10.3390/ijms10020407.
- Foy CJ, Passmore AP, Vahidassr MD, Young IS, Lawson JT. Plasma chain-breaking antioxidants in Alzheimer’s disease, vascular dementia and Parkinson’s disease. QJM. 1999;92(1):39–45. doi:https://doi.org/10.1093/qjmed/92.1.39.
- Ihara Y, Hayabara T, Sasaki K, Fujisawa Y, Kawada R, Yamamoto T, Nakashima Y, Yoshimune S, Kawai M, Kibata M, et al. Free radicals and superoxide dismutase in blood of patients with Alzheimer’s disease and vascular dementia. J Neurol Sci. 1997;153(1):76–81. doi:https://doi.org/10.1016/S0022-510X(97)00172-X.
- Thompson PM, Jahanshad N. Ironing out neurodegeneration: is iron intake important during the teenage years? Expert Rev Neurother. 2012;12(6):629–31. doi:https://doi.org/10.1586/ern.12.56.
- Hardy JA, Higgins GA. Alzheimer’s disease: the amyloid cascade hypothesis. Science. 1992;256(5054):184–5. doi:https://doi.org/10.1126/science.1566067.
- Migliore L, Fontana I, Trippi F, Colognato R, Coppedè F, Tognoni G, Nucciarone B, Siciliano G. Oxidative DNA damage in peripheral leukocytes of mild cognitive impairment and AD patients. Neurobiol Aging. 2005;26(5):567–73. doi:https://doi.org/10.1016/j.neurobiolaging.2004.07.016.
- Halliwell B. Oxidative stress and neurodegeneration: where are we now? J Neurochem. 2006;97(6):1634–58. doi:https://doi.org/10.1111/j.1471-4159.2006.03907.x.
- Casado A, Encarnacion Lopez-Fernandez M, Concepcion CM, de La TR. Lipid peroxidation and antioxidant enzyme activities in vascular and Alzheimer dementias. Neurochem Res. 2008;33(3):450–8. doi:https://doi.org/10.1007/s11064-007-9453-3.
- Cristalli DO, Arnal N, Marra FA, De Alaniz MJT, Marra CA. Peripheral markers in neurodegenerative patients and their first-degree relatives. J Neurol Sci. 2012;314(1-2):48–56. doi:https://doi.org/10.1016/j.jns.2011.11.001.
- Aksenov MY, Aksenova MV, Butterfield DA, Geddes JW, Markesbery WR. Protein oxidation in the brain in Alzheimer’s disease. Neuroscience. 2001;103(2):373–83. doi:https://doi.org/10.1016/S0306-4522(00)00580-7.
- Mecocci P, Tinarelli C, Schulz RJ, Polidori MC. Nutraceuticals in cognitive impairment and Alzheimer’s disease. Front Pharmacol. 2014;5::1–12. doi:https://doi.org/10.3389/fphar.2014.00147.
- Iijima K, Liu H-P, Chiang A-S, Hearn SA, Konsolaki M, Zhong Y. Dissecting the pathological effects of human Abeta40 and Abeta42 in Drosophila: a potential model for Alzheimer’s disease. Proc Natl Acad Sci USA. 2004;101(17):6623–8. doi:https://doi.org/10.1073/pnas.0400895101.
- Ferrero H, Larrayoz IM, Martisova E, Solas M, Howlett DR, Francis PT, Gil-Bea FJ, Martínez A, Ramírez MJ. Increased levels of brain adrenomedullin in the neuropathology of Alzheimer’s disease. Mol Neurobiol. 2018;55(6):5177–83. doi:https://doi.org/10.1007/s12035-017-0700-6.
- Braak H, Del Tredici K, Rüb U, De Vos RAI, Jansen Steur ENH, Braak E. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging. 2003;24(2):197–211. doi:https://doi.org/10.1016/S0197-4580(02)00065-9.
- Auluck PK, Chan HYE, Trojanowski JQ, Lee VM-Y, Bonini NM. Chaperone suppression of α-synuclein toxicity in a Drosophila model for Parkinson’s disease. Science. 2002;295(5556):865–8. doi:https://doi.org/10.1126/science.1067389.
- McLean PJ, Kawamata H, Shariff S, Hewett J, Sharma N, Ueda K, Breakefield XO, Hyman BT. TorsinA and heat shock proteins act as molecular chaperones: suppression of alpha-synuclein aggregation. J Neurochem. 2002;83(4):846–54.
- Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, Minoshima S, Yokochi M, Mizuno Y, Shimizu N. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature. 1998;392(6676):605–8. doi:https://doi.org/10.1038/33416.
- Lee FKM, Wong AKY, Lee YW, Wan OW, Edwin Chan HY, Chung KKK. The role of ubiquitin linkages on α-synuclein induced-toxicity in a Drosophila model of Parkinson’s disease. J Neurochem. 2009;110(1):208–19. doi:https://doi.org/10.1111/j.1471-4159.2009.06124.x.
- Krüger R, Kuhn W, Müller T, Woitalla D, Graeber M, Kösel S, Przuntek H, Epplen JT, Schöls L, Riess O. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson’s disease. Nat Genet. 1998;18(2):106–8. doi:https://doi.org/10.1038/ng0298-106.
- Braithwaite SP, Stock JB, Mouradian MM. α-Synuclein phosphorylation as a therapeutic target in Parkinson’s disease. Rev Neurosci. 2012;23(2):191–8. doi:https://doi.org/10.1515/revneuro-2011-0067.
- Bonifati V, Rizzu P, van Baren MJ, Schaap O, Breedveld GJ, Krieger E, Dekker MCJ, Squitieri F, Ibanez P, Joosse M, et al. Mutations in the DJ-1 gene associated with autosomal recessive early-onset Parkinsonism. Science. 2003;299(5604):256–9. doi:https://doi.org/10.1126/science.1077209.
- Azkona G, López de Maturana R, Del Rio P, Sousa A, Vazquez N, Zubiarrain A, Jimenez-Blasco D, Bolaños JP, Morales B, Auburger G, et al. LRRK2 expression is deregulated in fibroblasts and neurons from parkinson patients with mutations in PINK1. Mol Neurobiol. 2018;55(1):506–16. doi:https://doi.org/10.1007/s12035-016-0303-7.
- Xiong Y, Yu J. Modeling Parkinson’s disease in Drosophila: what have we learned for dominant traits? Front Neurol. 2018;9(APR):228. doi:https://doi.org/10.3389/fneur.2018.00228.
- McGurk L, Berson A, Bonini NM. Drosophila as an in vivo model for human neurodegenerative disease. Genetics. 2015;201(2):377–402. doi:https://doi.org/10.1534/genetics.115.179457.
- Thiruchelvam M, Brockel BJ, Richfield EK, Baggs RB, Cory-Slechta DA. Potentiated and preferential effects of combined paraquat and maneb on nigrostriatal dopamine systems: environmental risk factors for Parkinson’s disease? Brain Res. 2000;873(2):225–34. doi:https://doi.org/10.1016/S0006-8993(00)02496-3.
- Przedborski S, Jackson-Lewis V, Naini AB, Jakowec M, Petzinger G, Miller R, Akram M. The parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a technical review of its utility and safety. J Neurochem. 2001;76(5):1265–74. doi:https://doi.org/10.1046/j.1471-4159.2001.00183.x.
- Bayersdorfer F, Voigt A, Schneuwly S, Botella JA. Dopamine-dependent neurodegeneration in Drosophila models of familial and sporadic Parkinson’s disease. Neurobiol Dis. 2010;40(1):113–9. doi:https://doi.org/10.1016/j.nbd.2010.02.012.
- Wu Y-R, Wang C-K, Chen C-M, Hsu Y, Lin S-J, Lin Y-Y, Fung H-C, Chang K-H, Lee-Chen G-J. Analysis of heat-shock protein 70 gene polymorphisms and the risk of Parkinson’s disease. Hum Genet. 2004;114(3):236–41. doi:https://doi.org/10.1007/s00439-003-1050-1.
- Klucken J, Shin Y, Masliah E, Hyman BT, McLean PJ. Hsp70 reduces α-synuclein aggregation and toxicity. J Biol Chem. 2004;279(24):25497–502. doi:https://doi.org/10.1074/jbc.M400255200.
- Singh N, Bhalla M, de Jager P, Gilca M. An overview on Ashwagandha: a rasayana (rejuvenator) of ayurveda. Afr J Tradit Complement Altern Med. 2011;8(5 SUPPL):208–13. doi:https://doi.org/10.4314/ajtcam.v8i5S.9.
- Feany MB. New approaches to the pathology and genetics of neurodegeneration. Am J Pathol. 2010;176(5):2058–66. doi:https://doi.org/10.2353/ajpath.2010.091077.
- Cao X, Cao L, Ding L, Bian JS. A new hope for a devastating disease: hydrogen sulfide in Parkinson’s disease. Mol Neurobiol. 2018;55(5):3789–99. doi:https://doi.org/10.1007/s12035-017-0617-0.
- Nthenge-Ngumbau DN, Mohanakumar KP. Can cyclic nucleotide phosphodiesterase inhibitors be drugs for Parkinson’s disease? Mol Neurobiol. 2018;55(1):822–13. doi:https://doi.org/10.1007/s12035-016-0355-8.
- Neef DW, Turski ML, Thiele DJ. Modulation of heat shock transcription factor 1 as a therapeutic target for small molecule intervention in neurodegenerative disease. PLoS Biol. 2010;8(1):e1000291. doi:https://doi.org/10.1371/journal.pbio.1000291.
- Zou J, Guo Y, Guettouche T, Smith DF, Voellmy R. Repression of heat shock transcription factor HSF1 activation by HSP90 (HSP90 complex) that forms a stress-sensitive complex with HSF1. Cell. 1998;94(4):471–80. doi:https://doi.org/10.1016/S0092-8674(00)81588-3.
- Dutta D, Ali N, Banerjee E, Singh R, Naskar A, Paidi RK, Mohanakumar KP. Low levels of prohibitin in substantia nigra makes dopaminergic neurons vulnerable in Parkinson’s disease. Mol Neurobiol. 2018;55(1):804–18. doi:https://doi.org/10.1007/s12035-016-0328-y.
- Mutsuddi M, Nambu JR. Neural disease: Drosophila degenerates for a good cause. Curr Biol. 1998;8(22):R809–11. doi:https://doi.org/10.1016/s0960-9822(07)00506-4.
- Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, et al. Mutation in the -synuclein gene identified in families with Parkinson’s disease. Science. 1997;276(5321):2045–7. doi:https://doi.org/10.1126/science.276.5321.2045.
- Greene JC, Whitworth AJ, Kuo I, Andrews LA, Feany MB, Pallanck LJ. Mitochondrial pathology and apoptotic muscle degeneration in Drosophila parkin mutants. Proc Natl Acad Sci USA. 2003;100(7):4078–83. doi:https://doi.org/10.1073/pnas.0737556100.
- Whitworth AJ, Theodore D. a, Greene JC, Benes H, Wes PD, Pallanck LJ. Increased glutathione S-transferase activity rescues dopaminergic neuron loss in a Drosophila model of Parkinson’s disease. Proc Natl Acad Sci USA. 2005;102(22):8024–9. doi:https://doi.org/10.1073/pnas.0501078102.
- Di Monte DA. The environment and Parkinson’s disease: is the nigrostriatal system preferentially targeted by neurotoxins? Lancet Neurol. 2003;2(9):531–8. doi:https://doi.org/10.1016/S1474-4422(03)00501-5.
- Greenamyre JT, Betarbet R, Sherer TB. The rotenone model of Parkinson’s disease: genes, environment and mitochondria. Parkinson Relat Disord. 2003;9:59–64. doi:https://doi.org/10.1016/S1353-8020(03)00023-3.
- Sherer TB, Betarbet R, Stout AK, Lund S, Baptista M, Panov AV, Cookson MR, Greenamyre JT. An in vitro model of Parkinson’s disease: linking mitochondrial impairment to altered alpha-synuclein metabolism and oxidative damage. J Neurosci. 2002;22(16):7006–15. doi: https://doi.org/10.1523/JNEUROSCI.22-16-07006.2002.
- Coulom H, Birman S. Chronic exposure to rotenone models sporadic Parkinson’s disease in Drosophila melanogaster. J Neurosci. 2004;24(48):10993–8. doi:https://doi.org/10.1523/JNEUROSCI.2993-04.2004.
- Meulener M, Whitworth AJ, Armstrong-Gold CE, Rizzu P, Heutink P, Wes PD, Pallanck LJ, Bonini NM. Drosophila DJ-1 mutants are selectively sensitive to environmental toxins associated with Parkinson’s disease. Curr Biol. 2005;15(17):1572–7. doi:https://doi.org/10.1016/j.cub.2005.07.064.
- Müller TE, Nunes ME, Menezes CC, Marins AT, Leitemperger J, Gressler ACL, Carvalho FB, de Freitas CM, Quadros VA, Fachinetto R, et al. Sodium selenite prevents paraquat-induced neurotoxicity in zebrafish. Mol Neurobiol. 2018;55(3):1928–41. doi:https://doi.org/10.1007/s12035-017-0441-6.
- Fernandez-Funez P, Nino-Rosales ML, de Gouyon B, She WC, Luchak JM, Martinez P, Turiegano E, Benito J, Capovilla M, Skinner PJ, et al. Identification of genes that modify ataxin-1-induced neurodegeneration. Nature. 2000;408(6808):101–6. doi:https://doi.org/10.1038/35040584.
- Kazemi-Esfarjani P, Benzer S. Genetic suppression of polyglutamine toxicity in Drosophila. Science. 2000;287(5459):1837–40. doi:https://doi.org/10.1126/science.287.5459.1837.
- Bonini NM, Fortini ME. Human neurodegenerative disease modeling using Drosophila. Annu Rev Neurosci. 2003;26(1):627–56. doi:https://doi.org/10.1146/annurev.neuro.26.041002.131425.
- Furutani T, Takeyama K-i, Tanabe M, Koutoku H, Ito S, Taniguchi N, Suzuki E, Kudoh M, Shibasaki M, Shikama H, et al. Human expanded polyglutamine androgen receptor mutants in neurodegeneration as a novel ligand target. J Pharmacol Exp Ther. 2005;315(2):545–52. doi:https://doi.org/10.1124/jpet.105.087643.
- Bouleau S, Tricoire H. Drosophila models of Alzheimer’s disease: advances, limits, and perspectives. JAD. 2015;45(4):1015–38. doi:https://doi.org/10.3233/JAD-142802.
- DiFiglia M, Sapp E, Chase KO, Davies SW, Bates GP, Vonsattel JP, Aronin N. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science. 1997;277(5334):1990–3. doi:https://doi.org/10.1126/science.277.5334.1990.
- Davies SW, Turmaine M, Cozens BA, DiFiglia M, Sharp AH, Ross CA, Scherzinger E, Wanker EE, Mangiarini L, Bates GP. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell. 1997;90(3):537–48. doi:https://doi.org/10.1016/S0092-8674(00)80513-9.
- Lim K-L. Non-mammalian animal models of Parkinson’s disease for drug discovery. Expert Opin Drug Discov. 2010;5(2):165–76. doi:https://doi.org/10.1517/17460440903527675.
- Chen Y, Yang M, Deng J, Chen X, Ye Y, Zhu L, Liu J, Ye H, Shen Y, Li Y, et al. Expression of human FUS protein in Drosophila leads to progressive neurodegeneration. Protein Cell. 2011;2(6):477–86. doi:https://doi.org/10.1007/s13238-011-1065-7.
- Steffan JS, Bodai L, Pallos J, Poelman M, McCampbell A, Apostol BL, Kazantsev A, Schmidt E, Zhu Y-Z, Greenwald M, et al. Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature. 2001;413(6857):739–43. doi:https://doi.org/10.1038/35099568.
- Hockly E, Richon VM, Woodman B, Smith DL, Zhou X, Rosa E, Sathasivam K, Ghazi-Noori S, Mahal A, Lowden PAS, et al. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington’s disease. Proc Natl Acad Sci USA. 2003;100(4):2041–6. doi:https://doi.org/10.1073/pnas.0437870100.
- Warrick JM, Paulson HL, Gray-Board GL, Bui QT, Fischbeck KH, Pittman RN, Bonini NM. Expanded polyglutamine protein forms nuclear inclusions and causes neural degeneration in Drosophila. Cell. 1998;93(6):939–49. doi:https://doi.org/10.1016/S0092-8674(00)81200-3.
- Chan HYE, Bonini NM. Drosophila models of human neurodegenerative disease [Review]. Cell Death Differ. 2000;7(11):1075–80. doi:https://doi.org/10.1038/sj.cdd.4400757.
- Pesah Y, Pham T, Burgess H, Middlebrooks B, Verstreken P, Zhou Y, Harding M, Bellen H, Mardon G. Drosophila parkin mutants have decreased mass and cell size and increased sensitivity to oxygen radical stress. Development (Cambridge, England). 2004;131(9):2183–94. doi:https://doi.org/10.1242/dev.01095.
- Jansen RLM, Brogan B, Whitworth AJ, Okello EJ. Europe PMC funders group effects of five ayurvedic herbs on locomotor behaviour in a Drosophila melanogaster Parkinson’s disease model. Phytother Res. 2014;28(12):1789–95. doi:https://doi.org/10.1002/ptr.5199.Effects.
- Chow CY, Reiter LT. Etiology of human genetic disease on the fly. Trends Genet. 2017;33(6):391–8. doi:https://doi.org/10.1016/j.tig.2017.03.007.
- Bier E. Drosophila, the golden bug, emerges as a tool for human genetics. Nat Rev Genet. 2005;6(1):9–23. doi:https://doi.org/10.1038/nrg1503.
- Adams MD, Celniker SE, Holt RA, Evans CA, Gocayne JD, Amanatides PG, Scherer SE, Li PW, Hoskins RA, Galle RF. The genome sequence of Drosophila melanogaster. Science. 2000;287(5461):2185–95. doi:https://doi.org/10.1126/science.287.5461.2185.
- Bellen HJ, Levis RW, Liao G, He Y, Carlson JW, Tsang G, Evans-Holm M, Hiesinger PR, Schulze KL, Rubin GM, et al. The BDGP gene disruption project: single transposon insertions associated with 40% of Drosophila genes. Genetics. 2004;167(2):761–81. doi:https://doi.org/10.1534/genetics.104.026427.
- Venken KJT, Bellen HJ, Transgenesis upgrades for Drosophila melanogaster. Development. 2007;134(20):3571–84. doi:https://doi.org/10.1242/dev.005686.
- Kalra EK. Nutraceutical–definition and introduction. AAPS PharmSci. 2003;5(3):E25. doi:https://doi.org/10.1208/ps050325.
- Kalra EK. Nutraceutical–definition and introduction. AAPS PharmSci. 2003;5(3):27–8. doi:https://doi.org/10.1208/ps050325.
- Prasad C. Improving mental health through nutrition: the future. Nutr Neurosci. 2001;4(4):251–72. doi: https://doi.org/10.1080/1028415X.2001.11747367.
- Hardy G, Hardy I, Ball PA. Nutraceuticals–a pharmaceutical viewpoint: part II. Curr Opin Clin Nutr Metabol Care. 2003;6(0):661–71. doi:https://doi.org/10.1097/00075197-200311000-00010.
- Aliev G, Seyidova D, Neal ML, Shi J, Lamb BT, Siedlak SL, Vinters HV, Head E, Perry G, Lamanna JC, et al. Atherosclerotic lesions and mitochondria DNA deletions in brain microvessels as a central target for the development of human AD and AD-like pathology in aged transgenic mice. Ann N Y Acad Sci. 2002;977(1):45–64. doi: https://doi.org/10.1111/j.1749-6632.2002.tb04798.x.
- Mast JD, Tomalty KMH, Vogel H, Clandinin TR. Reactive oxygen species act remotely to cause synapse loss in a Drosophila model of developmental mitochondrial encephalopathy. Development (Cambridge, England). 2008;135(15):2669–79. doi:https://doi.org/10.1242/dev.020644.
- Chan CS, Gertler TS, Surmeier DJ. Calcium homeostasis, selective vulnerability and Parkinson’s disease. Trends Neurosci. 2009;32(5):249–56. doi:https://doi.org/10.1016/j.tins.2009.01.006.
- Wassef R, Haenold R, Hansel A, Brot N, Heinemann SH, Hoshi T. Methionine sulfoxide reductase A and a dietary supplement S-methyl-L-cysteine prevent Parkinson’s-like symptoms. J Neurosci. 2007;27(47):12808–16. doi:https://doi.org/10.1523/JNEUROSCI.0322-07.2007.
- Lemkul JA, Bevan DR. Morin inhibits the early stages of amyloid β-peptide aggregation by altering tertiary and quaternary interactions to produce “off-pathway” structures. Biochemistry. 2012;51(30):5990–6009. doi:https://doi.org/10.1021/bi300113x.
- Srinivasan K. Critical reviews in food science and nutrition antioxidant potential of spices and their active constituents antioxidant potential of spices and their active constituents. Crit Rev Food Sci Nutr. 2014;54(3):352–72. doi:https://doi.org/10.1080/10408398.2011.585525.
- Zhang Z-t, Cao X-b, Xiong N, Wang H-c, Huang J-s, Sun S-g, Wang T. Morin exerts neuroprotective actions in Parkinson disease models in vitro and in vivo. Acta Pharmacol Sin. 2010;31(8):900–6. doi:https://doi.org/10.1038/aps.2010.77.
- Yang F, Lim GP, Begum AN. Curcumin inhibits formation of amyloid β oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem. 2005;280(7):5892–5901. doi:https://doi.org/10.1074/jbc.M404751200.
- Ono K, Hasegawa K, Naiki H, Yamada M. Curcumin has potent anti-amyloidogenic effects for Alzheimer’s β-amyloid fibrils in vitro. J Neurosci Res. 2004;742–50. doi:https://doi.org/10.1002/jnr.
- Frautschy SA, Hu W, Kim P. Phenolic anti-inflammatory antioxidant reversal of Abeta-induced cognitive deficits and neuropathology. Neurobiol Aging. 2001;22(6):993–1005. doi: https://doi.org/10.1016/S0197-4580(01)00300-1.
- Ambegaokar SS, Wu L, Alamshahi K. Curcumin inhibits dose-dependently and time-dependently neuroglial cell proliferation and growth. Neuroendocrinol Lett. 2003;24(6):469.
- Pandey N, Strider J, Nolan WC, Yan SX, Galvin JE. Curcumin inhibits aggregation of α-synuclein. Acta Neuropathol. 2008;115(4):479–89. doi:https://doi.org/10.1007/s00401-007-0332-4.
- Peng Q, Buz’Zard AR, Lau BHS. Neuroprotective effect of garlic compounds in amyloid-beta peptide-induced apoptosis in vitro. Med Sci Monit. 2002;8(8):BR328-BR337.
- Gupta VB, Indi SS, Rao KSJ. Garlic extract exhibits antiamyloidogenic activity on amyloid-beta fibrillogenesis: relevance to Alzheimer’s disease. Phyther Res. 2009;23: 111–5. doi:https://doi.org/10.1002/ptr.2574.
- Gupta VB, Rao KSJ. Anti-amyloidogenic activity of S-allyl-L-cysteine and its activity to destabilize Alzheimer’s beta-amyloid fibrils in vitro. Neurosci Lett. 2007;429(2-3):75–80. doi:https://doi.org/10.1016/j.neulet.2007.09.042.
- Iuvone T, De Filippis D, Esposito G, D'Amico A, Izzo AA. The spice sage and its active ingredient rosmarinic acid protect PC12 cells from amyloid-beta peptide-induced neurotoxicity. J Pharmacol Exp Ther. 2006;317(3):1143–9. doi:https://doi.org/10.1124/jpet.105.099317
- Jukic M, Politeo O, Maksimovic M. In vitro acetylcholinesterase inhibitory properties of thymol, carvacrol and their derivatives thymoquinone and thymohydroquinone. Phyther Res. 2007;21: 259–61. doi:https://doi.org/10.1002/ptr.2063.
- Chonpathompikunlert P, Wattanathorn J, Muchimapura S. Piperine, the main alkaloid of Thai black pepper, protects against neurodegeneration and cognitive impairment in animal model of cognitive deficit like condition of Alzheimer’s disease. Food Chem Toxicol. 2010;48(3):798–802. doi: https://doi.org/10.1016/j.fct.2009.12.009.
- Guo JP, Yu S, McGeer PL. Simple in vitro assays to identify amyloid-β aggregation blockers for Alzheimer’s disease therapy. J Alzheimers Dis. 2010;19(4):1359–70. doi:https://doi.org/10.3233/JAD-2010-1331.
- Kabuto H, Nishizawa M, Tada M, Higashio C, Shishibori T, Kohno M. Zingerone [4-(4-hydroxy-3-methoxyphenyl)-2-butanone] prevents 6-hydroxydopamine-induced dopamine depression in mouse striatum and increases superoxide scavenging activity in serum. Neurochem Res. 2005;30(3):325–32. doi: https://doi.org/10.1007/s11064-005-2606-3.
- Yan JJ, Kim DH, Moon YS. Protection against β-amyloid peptide-induced memory impairment with long-term administration of extract of Angelica gigas or decursinol in mice. Prog Neuro-Psychopharmacol Biol Psychiatry. 2004;28(1):25–30. doi: https://doi.org/10.1016/S0278-5846(03)00168-4.
- Kabuto H, Tada M, Kohno M. Eugenol [2-methoxy-4-(2-propenyl) phenol] prevents 6-hydroxydopamine-induced dopamine depression and lipid peroxidation inductivity in mouse striatum. Biol Pharm Bull. 2007;30(3):423–7.
- Schmitz K, Barthelmes J, Stolz L. “Disease modifying nutricals” for multiple sclerosis. Pharmacol Ther. 2015;148:85–113.
- Kim J-H. Astaxanthin inhibits H2O2-mediated apoptotic cell death in mouse neural progenitor cells via modulation of P38 and MEK signaling pathways. J Microbiol Biotechnol. 2009;19(11):1355–63. doi:https://doi.org/10.4014/jmb.0906.06003.
- Pocernich CB, Lange ML, Sultana RA, Butterfield DA. Nutritional approaches to modulate oxidative stress in Alzheimers disease. Curr Alzheimer Res. 2011;8(5):452–69. doi:https://doi.org/10.2174/156720511796391908.
- Ogle WO, Speisman RB, Ormerod BK. Potential of treating age-related depression and cognitive decline with nutraceutical approaches: a mini-review. Gerontology. 2012;59(1):23–31.
- Cleren C, Yang L, Lorenzo B. Therapeutic effects of coenzyme Q10 (CoQ10) and reduced CoQ10 in the MPTP model of Parkinsonism. J Neurochem. 2008;104(6):1613–21. doi:https://doi.org/10.1111/j.1471-4159.2007.05097.x.
- Melli G, Taiana M, Camozzi F. Alpha-lipoic acid prevents mitochondrial damage and neurotoxicity in experimental chemotherapy neuropathy. Exp Neurol. 2008;214(2):276–84. doi:https://doi.org/10.1016/j.expneurol.2008.08.013.
- Sternberg Z, Chadha K, Lieberman A. Quercetin and interferon-beta modulate immune response(s) in peripheral blood mononuclear cells isolated from multiple sclerosis patients. J Neuroimmunol. 2008;205: 142–47. doi:https://doi.org/10.1016/j.jneuroim.2008.09.008.
- Kraft AD. Nuclear factor E2-related factor 2-dependent antioxidant response element activation by tert-butylhydroquinone and sulforaphane occurring preferentially in astrocytes conditions neurons against oxidative insult. J Neurosci. 2004;24(5)1101–12. doi:https://doi.org/10.1523/JNEUROSCI.3817-03.2004.
- Brewer GJ, Torricelli JR, Lindsey AL. Age-related toxicity of amyloid-beta associated with increased pERK and pCREB in primary hippocampal neurons: reversal by blueberry extract. J Nutr Biochem. 2010. doi:https://doi.org/10.1016/j.jnutbio.2009.08.005.
- Fuentealba J, Dibarrart AJ, Fuentes-Fuentes MC. Synaptic failure and adenosine triphosphate imbalance induced by amyloid-β aggregates are prevented by blueberry-enriched polyphenols extract. J Neurosci Res. 2011;21(10):991–8. doi:https://doi.org/10.1002/jnr.22679.
- Kelsey NA, Wilkins HM, Linseman DA. Nutraceutical antioxidants as novel neuroprotective agents. Molecules. 2010;15(11):7792–814. doi:https://doi.org/10.3390/molecules15117792.
- Sun GY, Xu J, Jensen MD, Simonyi A. Phospholipase A2 in the central nervous system: implications for neurodegenerative diseases. J Lipid Res. 2004;45(2):205–13. doi:https://doi.org/10.1194/jlr.R300016-JLR200.
- Fragoso YD, Stoney PN, McCaffery PJ. The evidence for a beneficial role of vitamin A in multiple sclerosis. CNS Drugs. 2014;28(4):291–9. doi:https://doi.org/10.1007/s40263-014-0148-4.
- Miller JW, Selhub J, Nadeau MR, Thomas CA, Feldman RG, Wolf PA. Effect of L-dopa on plasma homocysteine in PD patients: relationship to B-vitamin status. Neurology. 2003;60(7):1125–9. doi:https://doi.org/10.1212/01.WNL.0000055899.24594.8E.
- Lamberti P, Zoccolella S, Armenise E, Lamberti SV, Fraddosio A, Mari M, Iliceto G, Livrea P. Hyperhomocysteinemia in L-dopa treated Parkinson’s disease patients: effect of cobalamin and folate administration. Eur J Neurol. 2005;12(5):365–8. doi:https://doi.org/10.1111/j.1468-1331.2004.00973.x.
- Yokoyama H, Kuroiwa H, Tsukada T, Uchida H, Kato H, Araki T. Poly(ADP-ribose)polymerase inhibitor can attenuate the neuronal death after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in mice. J Neurosci Res. 2010;88(7):1522–36. doi:https://doi.org/10.1002/jnr.22310.
- Fahn S. An open trial of high-dosage antioxidants in early Parkinson’s disease. Am J Clin Nutr. 1991;53(1):380S–382S.
- Etminan M, Gill SS, Samii A. Intake of vitamin E, vitamin C, and carotenoids and the risk of Parkinson’s disease: a meta-analysis. Lancet Neurol. 2005;4(6):362–65.
- Gianforcaro A, Hamadeh MJ. Vitamin D as a potential therapy in amyotrophic lateral sclerosis. CNS Neurosci Ther. 2014;20(2):101–11. doi: https://doi.org/10.1111/cns.12204.
- Betti M, Minelli A, Ambrogini P, Ciuffoli S, Viola V, Galli F, Canonico B, Lattanzi D, Colombo E, Sestili P, et al. Dietary supplementation with α-tocopherol reduces neuroinflammation and neuronal degeneration in the rat brain after kainic acid-induced status epilepticus. Free Radic Res. 2011;45(10):1136–42. doi:https://doi.org/10.3109/10715762.2011.597750.
- Wang J, Ho L, Zhao W, Ono K, Rosensweig C, Chen L, Humala N, Teplow DB, Pasinetti GM. Grape-derived polyphenolics prevent a oligomerization and attenuate cognitive deterioration in a mouse model of Alzheimer’s disease. J Neurosci. 2008;28(25):6388–92. doi:https://doi.org/10.1523/JNEUROSCI.0364-08.2008.
- Pu H, Guo Y, Zhang W, Huang L, Wang G, Liou AK, Zhang J, Zhang P, Leak RK, Wang Y, et al. Omega-3 polyunsaturated fatty acid supplementation improves neurologic recovery and attenuates white matter injury after experimental traumatic brain injury. J Cereb Blood Flow Metab. 2013;33(9):1474–84. doi: https://doi.org/10.1038/jcbfm.2013.108.
- Losi G, Puia G, Garzon G. Apigenin modulates GABAergic and glutamatergic transmission in cultured cortical neurons. Eur J Pharmacol. 2004;502(1-2):41–6. doi:https://doi.org/10.1016/j.ejphar.2004.08.043.
- Lee HY, Kim HJ, Kim JM, Chang N. Effects of dietary folic acid supplementation on cerebrovascular endothelial dysfunction in rats with induced hyperhomocysteinemia. Brain Res. 2004;996: 139–47. doi:https://doi.org/10.1016/j.brainres.2003.10.027.
- Mizuno M, Kawamura H, Takei N, Nawa H. The anthraquinone derivative emodin ameliorates neurobehavioral deficits of a rodent model for schizophrenia. J Neural Transm. 2008;115(3):521–30. doi:https://doi.org/10.1007/s00702-007-0867-5.
- Theoharides TC. Luteolin as a therapeutic option for multiple sclerosis. J Neuroinflammation. 2009;6(1):29. doi:https://doi.org/10.1186/1742-2094-6-29.
- Denny Joseph KM. Muralidhara Combined oral supplementation of fish oil and quercetin enhances neuroprotection in a chronic rotenone rat model: relevance to Parkinson’s disease. Neurochem Res. 2015;40(5):894–905. doi:https://doi.org/10.1007/s11064-015-1542-0.
- Spencer JPE, Jenner A, Aruoma OI. Intense oxidative DNA damage promoted by l-DOPA and its metabolites implications for neurodegenerative disease. FEBS Lett. 1994;353(3):246–50. doi: https://doi.org/10.1016/0014-5793(94)01056-0.
- Patil RR, Gholave AR, Jadhav JP, Yadav SR, Bapat VA. Mucuna sanjappae Aitawade et Yadav: a new species of Mucuna with promising yield of anti-Parkinson’s drug L-DOPA. Genet Resour Crop Evol. 2015;62(1):155–62. doi: https://doi.org/10.1007/s10722-014-0164-8.
- Fang SC, Hsu CL, Yen GC. 2008. Anti-inflammatory effects of phenolic compounds isolated from the fruits of Artocarpus heterophyllus. J Agric Food Chem. 2008;56(12):4463–68. doi:https://doi.org/10.1021/jf800444g.
- Chen XC, Zhou YC, Chen Y. Ginsenoside Rg1 reduces MPTP-induced substantia nigra neuron loss by suppressing oxidative stress. Acta Pharmacol Sin. 2005;26(1):56–62. doi:https://doi.org/10.1111/j.1745-7254.2005.00019.x.
- Xu L, Chen WF, Wong MS. Ginsenoside Rg1 protects dopaminergic neurons in a rat model of Parkinson’s disease through the IGF-I receptor signalling pathway. Br J Pharmacol. 2009;158(3):738–48. doi:https://doi.org/10.1111/j.1476-5381.2009.00361.x.
- Siddique YH, Mujtaba SF, Jyoti S, Naz F. GC-MS analysis of Eucalyptus citriodora leaf extract and its role on the dietary supplementation in transgenic Drosophila model of Parkinson’s disease. Food Chem Toxicol. 2013;55:29–35. doi:https://doi.org/10.1016/j.fct.2012.12.028.
- Wang Y-J, Thomas P, Zhong J-H, Bi F-F, Kosaraju S, Pollard A, Fenech M, Zhou X-F. Consumption of grape seed extract prevents amyloid-beta deposition and attenuates inflammation in brain of an Alzheimer’s disease mouse. Neurotox Res. 2009;15(1):3–14. doi:https://doi.org/10.1007/s12640-009-9000-x.
- Venkat Rao S, Muralidhara MG, Rajini S. Neuromodulatory potential of aqueous extracts of cumin, cinnamon: evidence from rotenone model in Drosophila: implications to Parkinson’s disease. Int J Neurol Res. 2016;2(4):297–307. doi:https://doi.org/10.17554/j.issn.2313-5611.2016.02.60.
- Bender A, Koch W, Elstner M, Schombacher Y, Bender J, Moeschl M, Gekeler F, Müller-Myhsok B, Gasser T, Tatsch K, et al. Creatine supplementation in Parkinson disease: a placebo-controlled randomized pilot trial. Neurology. 2006;67(7):1262–4. doi:https://doi.org/10.1212/01.wnl.0000238518.34389.12.
- Siddique YH, Ara G, Jyoti S, Afzal M. The dietary supplementation of nordihydroguaiaretic acid (NDGA) delayed the loss of climbing ability in drosophila model of Parkinson’s disease. J Diet Supplement. 2012;9(1):1–8. doi:https://doi.org/10.3109/19390211.2011.630716.
- Gongora-Alfaro JL. Caffeine as a preventive drug for Parkinson’s disease: epidemiologic evidence and experimental support. Rev Neurol. 2010;50(4):221–9.
- Rojas P, Montes P, Rojas C, Serrano-García N, Rojas-Castañeda JC. Effect of a phytopharmaceutical medicine, Ginko biloba extract 761, in an animal model of Parkinson’s disease: therapeutic perspectives. Nutrition. 2012;28(11-12):1081–8. doi:https://doi.org/10.1016/j.nut.2012.03.007.
- Ahmad M, Saleem S, Ahmad AS, Yousuf S, Ansari MA, Khan MB, Ishrat T, Chaturvedi RK, Agrawal AK, Islam F. Ginkgo biloba affords dose-dependent protection against 6-hydroxydopamine-induced parkinsonism in rats: neurobehavioural, neurochemical and immunohistochemical evidences. J Neurochem. 2005;93(1):94–104. doi:https://doi.org/10.1111/j.1471-4159.2005.03000.x.
- Jahromi SR, Haddadi M, Shivanandappa T, Ramesh SR. Attenuation of neuromotor deficits by natural antioxidants of Decalepis hamiltonii in transgenic Drosophila model of Parkinson’s disease. Neuroscience. 2015;293:136–50. doi:https://doi.org/10.1016/j.neuroscience.2015.02.048.
- Murcia MA, Jimenez AM, Martinez-Tome M. Evaluation of the antioxidant properties of Mediterranean and tropical fruits compared with common food additives. J Food Prot. 2001;64(12):2037–46. doi:https://doi.org/10.4315/0362-028X-64.12.2037.
- Chung YK. Inhibitory effect of ursolic acid purified from Origanum majorana L on the acetylcholinesterase. Mol Cells. 2001;11:137–43.
- Kongkeaw C, Dilokthornsakul P, Thanarangsarit P, Limpeanchob N, Norman Scholfield C. Meta-analysis of randomized controlled trials on cognitive effects of Bacopa monnieri extract. J Ethnopharmacol. 2014;151(1):528–35. doi:https://doi.org/10.1016/j.jep.2013.11.008.
- Ahmed T, Gilani AH. A comparative study of curcuminoids to measure their effect on inflammatory and apoptotic gene expression in an Aβ plus ibotenic acid-infused rat model of Alzheimer’s disease. Brain Res. 2011;1400:1–18. doi:https://doi.org/10.1016/j.brainres.2011.05.022.
- Hartman RE, Shah A, Fagan AM, Schwetye KE, Parsadanian M, Schulman RN, Finn MB, Holtzman DM. Pomegranate juice decreases amyloid load and improves behavior in a mouse model of Alzheimer’s disease. Neurobiol Dis. 2006;24(3):506–15.
- Waxman E. a, Emmer KL, Giasson BI. 2010. Residue Glu83 plays a major role in negatively regulating alpha-synuclein amyloid formation. Biochem Biophys Res Commun. 2010;391(3):1415–20. doi:https://doi.org/10.1016/j.bbrc.2009.12.079.
- Jiang M, Porat-Shliom Y, Pei Z. Baicalein reduces E46K α-synuclein aggregation in vitro and protects cells against E46K α-synuclein toxicity in cell models of familiar Parkinsonism. J Neurochem. 2010. https://doi.org/10.1111/j.1471-4159.2010.06752.x
- Baluchnejadmojarad T, Roghani M, Nadoushan MRJ, Bagheri M. Neuroprotective effect of genistein in 6-hydroxydopamine hemi-parkinsonian rat model. Phyther Res. 2009;23(1):1328–35. doi:https://doi.org/10.1002/ptr.2564.
- Kiriyama K, Ohtaki H, Kobayashi N, Murai N, Matsumoto M, Sasaki S, Sawa C, Satoh K, Matsunaga M, Shioda S. A nucleoprotein-enriched diet suppresses dopaminergic neuronal cell loss and motor deficit in mice with MPTP-induced Parkinson’s disease. J Mol Neurosci. 2015;55(3):803–11. doi:https://doi.org/10.1007/s12031-014-0432-2.
- Haleagrahara N, Siew CJ, Mitra NK, Kumari M. 2011. Neuroprotective effect of bioflavonoid quercetin in 6-hydroxydopamine-induced oxidative stress biomarkers in the rat striatum. Neurosci Lett. 2011;500(2):139–43. doi:https://doi.org/10.1016/j.neulet.2011.06.021.
- Safar MM, Abdallah DM, Arafa NM, Abdel-Aziz MT. 2010. Magnesium supplementation enhances the anticonvulsant potential of valproate in pentylenetetrazol-treated rats. Brain Res. 2010;1334:58–64. doi:https://doi.org/10.1016/j.brainres.2010.03.076.
- Giridharan VV, Thandavarayan RA, Konishi T. Effect of Shengmai-san on cognitive performance and cerebral oxidative damage in BALB/c mice. J Med Food. 2011;14(6):601–9. doi: https://doi.org/10.1089/jmf.2010.1362.
- Dong H, Zhang X, Qian Y. Mast cells and neuroinflammation. Med Sci Monit Basic Res. 2014;20:200–6. doi:https://doi.org/10.12659/MSMBR.893093.
- Gibellini L, Pinti M, Nasi M, Montagna JP, De Biasi S, Roat E, Bertoncelli L, Cooper EL, Cossarizza A. Quercetin and cancer chemoprevention. Evid-Based Complement Alternat Med. 2011;2011:1–15. doi:https://doi.org/10.1093/ecam/neq053.
- Orhan IE. Centella asiatica (L.) Urban: From traditional medicine to modern medicine with neuroprotective potential. Evid-Based Complement Alternat Med. 2012;2012:1–8. doi:https://doi.org/10.1155/2012/946259.
- Nishteswar K, Joshi H, Karra RD. Role of indigenous herbs in the management of Alzheimer’s disease. Anc Sci Life. 2014;34(1):3–7. doi:https://doi.org/10.4103/0257-7941.150763.
- Calderón-Garcidueñas L, Franco-Lira M, Mora-Tiscareño A, Medina-Cortina H, Torres-Jardón R, Kavanaugh M. Early Alzheimer’s and Parkinson’s disease pathology in urban children: friend versus foe responses - It is time to face the evidence. Biomed Res Int. 2013;2013:161687. doi:https://doi.org/10.1155/2013/161687.
- Nakamura T, Cho D-H, Lipton SA. Redox regulation of protein misfolding, mitochondrial dysfunction, synaptic damage, and cell death in neurodegenerative diseases. Exp Neurol. 2012;238(1):12–21. doi:https://doi.org/10.1016/j.expneurol.2012.06.032.
- Masters SL, O’Neill LAJ. Disease-associated amyloid and misfolded protein aggregates activate the inflammasome. Trends Mol Med. 2011;17(5):276–82. doi:https://doi.org/10.1016/j.molmed.2011.01.005.
- Iqbal K, Liu F, Gong CX, del Alonso AC, Grundke-Iqbal I. Mechanisms of tau-induced neurodegeneration. Acta Neuropathol. 2009;118(1):53–69. doi:https://doi.org/10.1007/s00401-009-0486-3.
- Matsuzaki K, Kato K, Yanagisawa K. Aβ polymerization through interaction with membrane gangliosides. Biochim Biophys Acta Mol Cell Biol Lipids. 2010;1801(8):868–77. doi:https://doi.org/10.1016/j.bbalip.2010.01.008.
- Yogiraj V, Goyal PK, Chauhan CS, Goyal A, Vyas B. Carica papaya Linn: an overview. Int J Herb Med. 2014;2(5 Part A):1–8.
- Saeed F, Arshad MU, Pasha I, Naz R, Batool R, Khan AA, Nasir MA, Shafique B. Nutritional and phyto-therapeutic potential of papaya (Carica Papaya Linn.): an overview. Int J Food Prop. 2014;17(7):1637–53. doi:https://doi.org/10.1080/10942912.2012.709210.
- Barbagallo M, Marotta F, Dominguez LJ. Oxidative stress in patients with Alzheimer’s disease : effect of extracts of fermented papaya powder. Mediat Inflamm. 2015;2015:1–6. doi:https://doi.org/10.1155/2015/624801.
- Kothari V, Seshadri S. Antioxidant activity of seed extracts of Annona squamosa and Carica papaya. Nutr Food Sci. 2010;40(4):403–8. doi:https://doi.org/10.1108/00346651011062050.
- Afrin S, Gasparrini M, Forbes-Hernandez TY, Reboredo-Rodriguez P, Mezzetti B, Varela-López A, Giampieri F, Battino M. Promising health benefits of the strawberry: a focus on clinical studies. J Agric Food Chem. 2016;64(22):4435–49. doi:https://doi.org/10.1021/acs.jafc.6b00857.
- Guo JP, Yu S, McGeer PL. Simple in vitro assays to identify amyloid-β aggregation blockers for Alzheimer’s disease therapy. JAD. 2010;19(4):1359–70. doi:https://doi.org/10.3233/JAD-2010-1331.
- Gil MI, Tomas-Barberan FA, Hess-Pierce B, Holcroft DM, Kader AA. Antioxidant activity of pomegranate juice and its relationship with phenolic composition and processing. J Agric Food Chem. 2000;48(10):4581–9. doi:https://doi.org/10.1021/jf000404a.
- Koyama S, Eden UT, Brown EN, Kass RE. Bayesian decoding of neural spike trains. Ann Inst Stat Math. 2010;62(1):37–59. doi:https://doi.org/10.1007/s10463-009-0249-x.
- Tapias V, Cannon JR, Greenamyre JT. Pomegranate juice exacerbates oxidative stress and nigrostriatal degeneration in Parkinson’s disease. Neurobiol Aging. 2014;35(5):1162–76. doi:https://doi.org/10.1016/j.neurobiolaging.2013.10.077.
- Mizrahi M, Friedman-Levi Y, Larush L, Frid K, Binyamin O, Dori D, Fainstein N, Ovadia H, Ben-Hur T, Magdassi S, et al. Pomegranate seed oil nanoemulsions for the prevention and treatment of neurodegenerative diseases : the case of genetic CJD. Nanomed Nanotechnol Biol Med. 2014;10(6):1353–63. doi:https://doi.org/10.1016/j.nano.2014.03.015.
- Essa M, Subash S, Braidy N, Al-Adawi S, Al-Asmi A, Al-Senawi H, Vaishnav R, Guillemin GJ. Neuroprotective effects of pomegranate juice extracts on quinolinic acid–induced excitotoxicity in human neurons. Alzheimer’s Dement. 2013;9(4):P800–1. doi:https://doi.org/10.1016/j.jalz.2013.05.1653.
- Nakano D, Itoh C, Takaoka M, Kiso Y, Tanaka T, Matsumura Y. Antihypertensive effect of sesamin. IV. Inhibition of vascular superoxide production by sesamin. Biol Pharm Bull. 2002;25(9):1247–9. doi:https://doi.org/10.1248/bpb.25.1247.
- Nakano D, Kwak C-J, Fujii K, Ikemura K, Satake A, Ohkita M, Takaoka M, Ono Y, Nakai M, Tomimori N, et al. Sesamin metabolites induce an endothelial nitric oxide-dependent vasorelaxation through their antioxidative property-independent mechanisms: possible involvement of the metabolites in the antihypertensive effect of sesamin. J Pharmacol Exp Ther. 2006;318(1):328–35. doi:https://doi.org/10.1124/jpet.105.100149.
- Yamashita K, Nohara Y, Katayama K, Namiki M. Sesame seed lignans and gamma-tocopherol act synergistically to produce vitamin E activity in rats. J Nutr. 1992;122(12):2440–6. doi:https://doi.org/10.1093/jn/122.12.2440.
- Jeng K, Hou R. Sesamin and sesamolin: natures therapeutic lignans. CEI. 2005;1(1):11–20. doi:https://doi.org/10.2174/1573408052952748.
- Zuo Y, Peng C, Liang Y, Ma KY, Chan HYE, Huang Y, Chen ZY. Sesamin extends the mean lifespan of fruit flies. Biogerontology. 2013;14(2):107–19. doi:https://doi.org/10.1007/s10522-012-9413-4.
- Singh MP, Hamid H, Himalian R. Neuroprotective potential of Bacopa monnieri, Camellia sinensis and curcumin on chlorpyrifos exposed Drosophila melanogaster. Toxico Int. 2021;28(1):7–11. doi:https://doi.org/10.18311/ti/2021/v28i1/23504.
- Ahmed T, Gilani AH. Therapeutic potential of turmeric in Alzheimer’s disease: Curcumin or curcuminoids? Phytother Res. 2014;28(4):517–25. doi:https://doi.org/10.1002/ptr.5030.
- Lim GP, Chu T, Yang F, Beech W, Frautschy S. a, Cole GM. The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J Neurosci. 2001;21(21):8370–7. doi:https://doi.org/10.1523/JNEUROSCI.21-21-08370.2001.
- Agrawal R, Mishra B, Tyagi E, Nath C, Shukla R. Effect of curcumin on brain insulin receptors and memory functions in STZ (ICV) induced dementia model of rat. Pharmacol Res. 2010;61(3):247–52. doi:https://doi.org/10.1016/j.phrs.2009.12.008.
- Isik AT, Celik T, Ulusoy G, Ongoru O, Elibol B, Doruk H, Bozoglu E, Kayir H, Mas MR, Akman S. Curcumin ameliorates impaired insulin/IGF signalling and memory deficit in a streptozotocin-treated rat model. Age. 2009;31(1):39–49. doi:https://doi.org/10.1007/s11357-008-9078-8.
- Zbarsky V, Datla KP, Parkar S, Rai DK, Aruoma OI, Dexter DT. Neuroprotective properties of the natural phenolic antioxidants curcumin and naringenin but not quercetin and fisetin in a 6-OHDA model of Parkinson’s disease. Free Radical Res. 2005;39(10):1119–25. doi:https://doi.org/10.1080/10715760500233113.
- Lapchak PA. Neuroprotective and neurotrophic curcuminoids to treat stroke: a translational perspective. Expert Opin Investig Drugs. 2011;20(1):13–22. doi:https://doi.org/10.1517/13543784.2011.542410.
- Singh MP, Mishra M, Sharma A, Shukla AK, Mudiam MKR, Patel DK, Ram KR, Chowdhuri DK. Genotoxicity and apoptosis in Drosophila melanogaster exposed to benzene, toluene and xylene: attenuation by quercetin and curcumin. Toxicol Appl Pharmacol. 2011;253(1):14–30. doi:https://doi.org/10.1016/j.taap.2011.03.006.
- Kunnumakkara AB, Bordoloi D, Harsha C, Banik K, Gupta SC, Aggarwal BB. Curcumin mediates anticancer effects by modulating multiple cell signaling pathways. Clin Sci (Lond). 2017;131(15):1781–99. doi:https://doi.org/10.1042/CS20160935.
- Yadav CS, Kumar V, Suke SG, Ahmed RS, Mediratta PK, Banerjee BD. Propoxur-induced acetylcholine esterase inhibition and impairment of cognitive function: attenuation by Withania somnifera. Indian J Biochem Biophys. 2010;47(2):117–20.
- Grover A, Shandilya A, Punetha A, Bisaria VS, Sundar D. Inhibition of the NEMO/IKKβ association complex formation, a novel mechanism associated with the NF-κB activation suppression by Withania somnifera’s key metabolite withaferin A. BMC Genomics. 2010;11(SUPPL. 4):S25. doi:https://doi.org/10.1186/1471-2164-11-S4-S25.
- Sehgal N, Gupta A, Valli RK, Joshi SD, Mills JT, Hamel E, Khanna P, Jain SC, Thakur SS, Ravindranath V. Withania somnifera reverses Alzheimer’s disease pathology by enhancing low-density lipoprotein receptor-related protein in liver. Proc Natl Acad Sci USA. 2012;109(9):3510–5. doi:https://doi.org/10.1073/pnas.1112209109.
- Peth-Nui T, Wattanathorn J, Muchimapura S, Tong-Un T, Piyavhatkul N, Rangseekajee P, Ingkaninan K, Vittaya-Areekul S. Effects of 12-week bacopa monnieri consumption on attention, cognitive processing, working memory, and functions of both cholinergic and monoaminergic systems in healthy elderly volunteers. Evid Based Complement Alternat Med. 2012;2012:606424. doi:https://doi.org/10.1155/2012/606424.
- Santos R, Ursu O, Gaulton A, Bento AP, Donadi RS, Bologa CG, Karlsson A, Al-Lazikani B, Hersey A, Oprea TI, et al. A comprehensive map of molecular drug targets. Nat Rev Drug Discov. 2017;16(1):19–34. doi:https://doi.org/10.1038/nrd.2016.230.
- Saraf MK, Prabhakar S, Anand A. Neuroprotective effect of Bacopa monniera on ischemia induced brain injury. Pharmacol Biochem Behav. 2010;97(2):192–7. doi:https://doi.org/10.1016/j.pbb.2010.07.017.
- Mathew J, Peeyush Kumar T, Khan RS, Paulose CS. Behavioral deficit and decreased GABA receptor functional regulation in the cerebellum of epileptic rats: effect of Bacopa monnieri and bacoside A. Epilepsy and Behav. 2010;17(4):441–7. doi:https://doi.org/10.1016/j.yebeh.2010.01.012.
- Zhao L, Wang JL, Wang YR, Fa XZ. Apigenin attenuates copper-mediated β-amyloid neurotoxicity through antioxidation, mitochondrion protection and MAPK signal inactivation in an AD cell model. Brain Res. 2013;1492:33–45. doi:https://doi.org/10.1016/j.brainres.2012.11.019.
- Kumar A, Christian PK, Panchal K, Guruprasad BR, Tiwari AK. Supplementation of spirulina (Arthrospira platensis) improves lifespan and locomotor activity in paraquat-sensitive DJ-1βΔ93Flies, a Parkinson’s disease model in Drosophila melanogaster. J Diet Suppl. 2017;14(5):573–88. doi:https://doi.org/10.1080/19390211.2016.1275917.
- Zhang S, Binari R, Zhou R, Perrimon N. A genomewide RNA interference screen for modifiers of aggregates formation by mutant huntingtin in drosophila. Genetics. 2010;184(4):1165–79. doi:https://doi.org/10.1534/genetics.109.112516.
- Ates O, Cayli S, Altinoz E, Gurses I, Yucel N, Sener M, Kocak A, Yologlu S. Neuroprotection by resveratrol against traumatic brain injury in rats. Mol Cell Biochem. 2007;294(1-2):137–44. doi:https://doi.org/10.1007/s11010-006-9253-0.
- West T, Atzeva M, Holtzman DM. Pomegranate polyphenols and resveratrol protect the neonatal brain against hypoxic-ischemic injury. Dev Neurosci. 2007;29(4-5):363–72. doi:https://doi.org/10.1159/000105477.
- Karalis F, Soubasi V, Georgiou T, Nakas CT, Simeonidou C, Guiba-Tziampiri O, Spandou E. Resveratrol ameliorates hypoxia/ischemia-induced behavioral deficits and brain injury in the neonatal rat brain. Brain Res. 2011;1425:98–110. doi:https://doi.org/10.1016/j.brainres.2011.09.044.
- Simao F, Matte A, Breier AC, Kreutz F, Trindade VM, Netto CA, Salbego CG. Resveratrol prevents global cerebral ischemia-induced decrease in lipid content. Neurol Res. 2013;35(1):59–64. doi:https://doi.org/10.1179/1743132812Y.0000000116.
- Tan Y, Yu F, Pereira A, Morin P, Zhou J. Suppression of Nrdp1 toxicity by Parkin in Drosophila models. Biochem Biophys Res Commun. 2011;416(1-2):18–23. doi:https://doi.org/10.1016/j.bbrc.2011.10.104.
- Orsu P, Murthy BVSN, Akula A. Cerebroprotective potential of resveratrol through anti-oxidant and anti-inflammatory mechanisms in rats. J Neural Transm. 2013;120(8):1217–23. doi:https://doi.org/10.1007/s00702-013-0982-4.
- Lin Y, Chen F, Zhang J, Wang T, Wei X, Wu J, Feng Y, Dai Z, Wu Q. Neuroprotective effect of resveratrol on ischemia/reperfusion injury in rats through TRPC6/CREB pathways. J Mol Neurosci. 2013;50(3):504–13. doi:https://doi.org/10.1007/s12031-013-9977-8.
- Barreira JCM, Ferreira ICFR, Oliveira MBPP, Pereira JA. Antioxidant potential of chestnut (Castanea sativa L.) and almond (Prunus dulcis L.) by-products. Food Sci Technol Int. 2010;16(3):209–16. doi:https://doi.org/10.1177/1082013209353983.
- Bolling BW, Chen C-YO, McKay DL, Blumberg JB. Tree nut phytochemicals: composition, antioxidant capacity, bioactivity, impact factors. A systematic review of almonds, Brazils, cashews, hazelnuts, macadamias, pecans, pine nuts, pistachios and walnuts. Nutr Res Rev. 2011;24(2):244–75. doi:https://doi.org/10.1017/S095442241100014X.
- Haider S, Batool Z, Haleem DJ. Nootropic and hypophagic effects following long term intake of almonds (Prunus amygdalus) in rats. Nutr Hosp. 2012;27(6):2109–15. doi:https://doi.org/10.3305/nh.2012.27.6.6140.
- Wijeratne SSK, Abou-Zaid MM, Shahidi F. Antioxidant polyphenols in almond and its coproducts. J Agric Food Chem. 2006;54(2):312–8. doi:https://doi.org/10.1021/jf051692j.
- Batool Z, Sadir S, Liaquat L, Tabassum S, Madiha S, Rafiq S, Tariq S, Batool TS, Saleem S, Naqvi F, et al. Repeated administration of almonds increases brain acetylcholine levels and enhances memory function in healthy rats while attenuates memory deficits in animal model of amnesia. Brain Res Bull. 2016;120:63–74. doi:https://doi.org/10.1016/j.brainresbull.2015.11.001.
- Suh S-J, Koo B-S, Jin U-H, Hwang M-J, Lee I-S, Kim C-H. Pharmacological characterization of orally active cholinesterase inhibitory activity of Prunus persica L. Batsch in rats. JMN. 2006;29(2):101–8. doi:https://doi.org/10.1385/JMN/29.
- Shadfar S, Kim Y-G, Katila N, Neupane S, Ojha U, Bhurtel S, Srivastav S, Jeong G-S, Park P-H, Hong JT, et al. Neuroprotective effects of antidepressants via upregulation of neurotrophic factors in the MPTP model of Parkinson’s disease. Mol Neurobiol. 2018;55(1):554–66. doi:https://doi.org/10.1007/s12035-016-0342-0.
- Kulkarni KS, Kasture SB, Mengi SA. Efficacy study of Prunus amygdalus (almond) nuts in scopolamine-induced amnesia in rats. Indian J Pharmacol. 2010;42(3):168–73. doi:https://doi.org/10.4103/0253-7613.66841.
- Willis LM, Shukitt-Hale B, Cheng V, Joseph JA. Dose-dependent effects of walnuts on motor and cognitive function in aged rats. Br J Nutr. 2009;101(8):1140–4. doi:https://doi.org/10.1017/S0007114508059369.
- Haider S, Batool Z, Tabassum S, Perveen T, Saleem S, Naqvi F, Javed H, Haleem DJ. Effects of walnuts (Juglans regia) on learning and memory functions. Plant Foods Hum Nutr. 2011;66(4):335–40. doi:https://doi.org/10.1007/s11130-011-0260-2.
- Essa MM, Subash S, Dhanalakshmi C, Manivasagam T, Al-Adawi S, Guillemin GJ, Thenmozhi AJ. Dietary supplementation of walnut partially reverses 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine induced neurodegeneration in a mouse model of Parkinson’s disease. Neurochem Res. 2015;40(6):1283–93. doi:https://doi.org/10.1007/s11064-015-1593-2.
- Long J, Gao H, Sun L, Liu J, Zhao-Wilson X. Grape extract protects mitochondria from oxidative damage and improves locomotor dysfunction and extends lifespan in a Drosophila Parkinson’s disease model. Rejuvenation Res. 2009;12(5):321–31. doi:https://doi.org/10.1089/rej.2009.0877.
- Khan S, Jyoti S, Naz F, Shakya B, Rahul AM, Siddique YH. Effect of L-ascorbic acid on the climbing ability and protein levels in the brain of Drosophila model of Parkinson’s disease. Int J Neurosci. 2012;122(12):704–9. doi:https://doi.org/10.3109/00207454.2012.709893.
- Siddique YH, Faisal M, Naz F, Jyoti S. Rahul Role of Ocimum sanctum leaf extract on dietary supplementation in the transgenic Drosophila model of Parkinson’s disease. Chin J Nat Med. 2014;12(10):777–81. doi:https://doi.org/10.1016/S1875-5364(14)60118-7.
- Brower V. Nutraceuticals: poised for a healthy slice of the healthcare market? Nat Biotechnol. 1998;16(8):728–31. doi:https://doi.org/10.1038/nbt0898-728.
- Rodriguez-Mateos A, Vauzour D, Krueger CG, Shanmuganayagam D, Reed J, Calani L, Mena P, Del Rio D, Crozier A. Bioavailability, bioactivity and impact on health of dietary flavonoids and related compounds: an update. Arch Toxicol. 2014;88(10):1803–53. doi:https://doi.org/10.1007/s00204-014-1330-7.
- Liu L-F, Song J-X, Lu J-H, Huang Y-Y, Zeng Y, Chen L-L, Durairajan SSK, Han Q-B, Li M. Tianma Gouteng Yin, a traditional Chinese medicine decoction, exerts neuroprotective effects in animal and cellular models of Parkinson’s disease. Sci Rep. 2015;5(1):1–11. doi:https://doi.org/10.1038/srep16862.